S100A9 and myelodysplastic syndrome: It is worth noting that downregulation of NLRP3 or caspase-1, neutralization of S100A9, and drug inhibition of NLRP3 or NOX inhibit MDS cell pyroptosis, ROS production, and nuclear β-catenin activity, which is sufficient to restore effective hematopoiesis [34].